For research use only
| Cat No. | ABC-X0044C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
This model expresses FGFR3-TACC3 (L608V) fusion for exploring the altered signaling, oncogenic transformation, and testing anti-FGFR therapies.
The FGFR3 TACC3 (L608V) BAF3 Cell Line expresses the FGFR3-TACC3 fusion gene carrying the L608V activating mutation in BAF3 cells. The mutation enhances kinase function and contributes to therapeutic resistance. Cells are stably transduced and validated for gene expression.
Target
FGFR3-TACC3 fusions drive glioblastoma and bladder cancer progression. The L608V mutation boosts kinase activation and modulates therapeutic response. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0044C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Used for functional studies of FGFR3-TACC3 signaling, resistance profiling, and development of FGFR-targeted therapeutics.